Doximity (NYSE:DOCS) Upgraded to “Moderate Buy” at Royal Bank Of Canada

Royal Bank Of Canada upgraded shares of Doximity (NYSE:DOCS) to a moderate buy rating in a report issued on Thursday morning,Zacks.com reports.

Several other equities research analysts have also recently weighed in on DOCS. Wall Street Zen cut Doximity from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Doximity in a research note on Wednesday, December 24th. The Goldman Sachs Group raised shares of Doximity from a “strong sell” rating to a “hold” rating in a report on Friday. Finally, Barclays upgraded shares of Doximity to a “strong-buy” rating in a research note on Monday, December 8th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy”.

Doximity Stock Performance

NYSE:DOCS opened at $43.85 on Thursday. The firm has a market cap of $8.26 billion, a P/E ratio of 34.80, a P/E/G ratio of 2.03 and a beta of 1.39. Doximity has a 52-week low of $43.21 and a 52-week high of $85.21.

Doximity News Roundup

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Truist upgraded DOCS from “hold” to “strong-buy,” signaling conviction in near-term upside and product/market momentum that could support a rebound in shares. Truist Upgrade
• Positive Sentiment: Royal Bank of Canada (RBC) moved DOCS to a “moderate buy,” citing a durable growth moat—this bolsters the long-term growth thesis and may attract buyers looking past recent volatility. RBC Coverage
• Positive Sentiment: Goldman Sachs upgraded DOCS from “strong sell” to “hold” — a move that reduces downside risk from a major house, even as Goldman warns of a valuation reset; the change can remove selling pressure tied to the prior very negative rating. Goldman Upgrade
• Neutral Sentiment: Coverage pieces assess DOCS vs. peers and provide a critical review of positioning—useful context for investors but not an immediate catalyst by themselves. Competitor Review
• Neutral Sentiment: Yahoo Finance examines valuation after volatile trading and discusses recent AI product updates; product developments are positive, but valuation and volatility keep the near-term outlook mixed. Valuation & AI Update
• Negative Sentiment: Wall Street Zen lowered DOCS to a “hold,” which could add selling pressure among investors who react to fresh downgrades and heighten short-term caution. Wall Street Zen Downgrade

Doximity Company Profile

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.